The RFC1 G80A polymorphism is closely associated with higher rates of methotrexate-induced toxicity in pediatric acute lymphoblastic leukemia (ALL), according to a study published in the World Journal ...
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended new measures to reduce the risk of dosing errors with medicines containing methotrexate.